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Background: Many studies suggested mesenchymal stem cells (MSCs) transplantation as a new approach to
control hyperglycemia in type 1 diabetes mellitus through differentiation mechanism. In contrary others believed
that therapeutic properties of MSCs is depends on paracrine mechanisms even if they were not engrafted. This
study aimed to compare these two approaches in control of hyperglycemia in STZ-induced diabetic rats.
Methods: Animals were divided into five groups: normal; diabetic control; diabetic received MSCs; diabetic received
supernatant of MSCs; diabetic received co-administration of MSCs with supernatant. Blood glucose, insulin levels
and body weight of animals were monitored during experiment. Immunohistochemical and immunofluorescence
analysis were performed to monitor functionality and migration of labeled-MSCs to pancreas.
Results: First administration of MSCs within the first 3 weeks could not reduce blood glucose, but second
administration significantly reduced blood glucose after week four compared to diabetic controls. Daily injection of
supernatant could not reduce blood glucose as efficient as MSCs. Interestingly; Co-administration of MSCs with
supernatant significantly reduced blood glucose more than other treated groups. Insulin levels and body weight
were significantly increased in MSCs + supernatant-treated animals compared to other groups. Immunohistological
analysis showed an increase in number and size of islets per section respectively in supernatant, MSCs and MSCs +
supernatant-treated groups.
Conclusion: Present study exhibited that repeated-injection of MSCs reduced blood glucose and increased
serum insulin levels in recipient rats. Injection of supernatant could not reverse hyperglycemia as efficient as
MSCs. Interestingly; co-administration of MSCs with supernatant could reverse hyperglycemia more than either
group alone.
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Type 1 diabetes mellitus (T1DM) is an autoimmune
disease in which β-cells are completely destroyed, resulting
in metabolic dysfunction as a consequence of insufficient
circulating levels of insulin [1,2]. Insulin therapy, as a
principal method of treatment, not only has relative* Correspondence: sharifalim@gmail.com
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unless otherwise stated.life-threatening complications but also do not able to
mimic exactly the physiology of insulin secretion in
the body [3]. The alternative method to treat diabetes are
transplantation of whole pancreas and/or pancreatic islets
cells [4]. Pancreatic islets transplantation has major limita-
tions, including inadequate organ donor and also many
complications of rejection reaction when xenogenic islet
cells have been used [5]. Hence, much effort has been
made to generate β cell mass either by stimulating en-
dogenous regeneration of islets or in vitro differentiation
of islet-like cells [6-8]. Many studies have revealed that. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Since MSCs could easily be isolated from bone marrow
and differentiated into a variety of cell types, being known
as the most commonly used stem cells in tissue engin-
eering and regenerative medicine [9,10]. The ability of
mesenchymal stem cells particularly bone marrow de-
rived (BM-MSCs) to differentiate into many cell types, as
well as their high expansion potential ex vivo, makes them
an attractive therapeutic tool for cell transplantation and
tissue engineering [11-14]. Several evidences suggested
that administration of MSCs have highly potential to
recover endogenous β cells in diabetes mellitus due to
their ability to differentiate into many cells and tissues
under specific condition [15-17]. However, the precise
function of BM-derived cells in β cell regeneration is
controversial. Some studies believe that therapeutic prop-
erties and use of MSCs would be primarily based on their
paracrine mechanisms by releasing trophic and immu-
nomodulatory factors. It has been demonstrated that
MSCs produce and release various growth factors and
cytokines including anti-apoptotic, immunomodulatory,
supportive, angiogenic, chemoattractic factors. These
studies indicated that MSCs are promising tools for
the treatment of different types of tissue damages,
because they secrete a multitude of bioactive mole-
cules that ultimately lead to reformation and regener-
ation of injured tissues [18-21]. Therefore, many studies
shift their focus from differentiation to paracrine mech-
anism in which MSCs could be used as therapeutic
tools, even if they do not engraft or differentiate into
tissue-specific cell [19,21,22]. It has been shown that
MSCs migrate and dock preferentially into the injured or
damaged tissue sites promoting the survival of surrounding
cells [21,23,24].
This study was designed to assess: [1] Beneficial effect
of supernatant of MSCsin control of hyperglycemia in
diabetic rats [2]. Comparative evaluation of MSCs trans-
plantation with their supernatant administration in con-
trol of hyperglycemia in diabetic rats [3]. The beneficial
effects of co-administration of MSCs with supernatant
in control of T1DM.
Material and methods
Animals
Eight-weeks-old male Wistar rats with initial body weights
of 200-250 g were used in this study. The rats were
divided into five groups, normal control, diabetic control,
MSCs- treated, supernatant- treated and MSCs + super-
natant treated group. Each group (n = 7) was housed in
individual standard cages at temperature of 20-25°C and
45-55% humidity under a 12/12 h light/dark cycle. All of
the experiments were carried out in accordance with the
guidelines of the Ethics Committee of Iran University of
Medical Sciences.Isolation and cultivation of rat bone marrow-derived
mesenchymal stem cells
Bone marrow (BM) was isolated from femurs and tibias of
two-month-old male Wistar rats (200–250 g) under asep-
tic condition. Wistar rats were euthanized by ketamine
(150 mg/kg, ip)- Xylazine (10 mg/kg, ip). Femur and Tibia
were dissected and soaked in cold PBS. Adherent soft tis-
sues was carefully removed. BM was exposed and aspirated
by forcing 4–5 ml cell culture medium. BM cells (including
hematopoietic stem cell and marrow stromal cells) were
cultured in minimal essential medium α (α-MEM, Gibco,
Invitrogen, Carlsbad, CA, USA) containing 15% fetal bovine
serum (FBS, Gibco, Invitrogen, Carlsbad, CA, USA) and 1%
penicillin/streptomycin (Gibco, Invitrogen, Carlsbad, CA,
USA) and incubated at 37°C and 5% CO2. After 24 h,
medium was changed and adherent cells were fed with
fresh medium every 2–3 days. After 10–14 days, adherent
cells formed homogenous fibroblast-like colonies. The
cells reach to passages 3–5 were used for following stud-
ies. Flowcytometry analysis was used for approving of
MSCs and their multipotent property.
Flow cytometry analysis of MSCs
Cultured MSCs were detached by Trypsin/EDTA and
washed twice with PBS. About 2× 105 of cells were incubated
with an appropriate concentrations of FITC-conjugated
monoclonal rat antimouse CD11b, CD31, CD34, CD44,
CD45, CD73, CD90, CD105 and CD106 for 40 min at 4°C
in the dark. The cells were washed by centrifugation for
5 min and resuspended in PBS. Quantitative fluorescence
analysis was carried out using FACS Calibur Cytometer
(Becton Dickinson, San Diego, CA, USA) and Cell Quest
software. At least 20 000 events were collected. All the ex-
periments also incubated with FITC- rat anti-mouse IgG1
as a negative isotype control.
STZ-induced diabetes in male Wistar rats
Diabetic groups received single intra peritoneal injection
of 65 mg/kg Streptozocin (STZ, Sigma-Aldrich, St. Louis,
MO, USA). The control group received sodium citrate
buffer. STZ was dissolved in sodium citrate buffer, pH 4.5,
and injected immediately after preparation. Blood glucose
levels were monitored before and after injection of STZ by
glucometer (GM300, Bionime Corporation, Taiwan).
During the experience, from day 3 to 42, blood glucose of
animals was measured weekly at 8:00–9:00 AM.
Mesenchymsl stem cells transplantation
Animals were anesthetized by injection of a mixture of keta-
mine hydrochloride (100 mg/kg, ip) and xylazine (5 mg/kg,
ip). The adherent MSCs were trypsinized and washed twice
with PBS and 2.5 × 106 cells/rat of MSCs in 1.0 ml saline
were injected through tail vein. Second transplantation of
MSCs was performed with interval of 20 days from the
Aali et al. Journal of Diabetes & Metabolic Disorders 2014, 13:76 Page 3 of 10
http://www.jdmdonline.com/content/13/1/76first transplantation. The same volume of normal saline
was injected into diabetic control groups.
Harvesting and administration of Supernatant of MSCs
MSCs of passage 3–5 were seeded for further expansion.
After the medium of MSCs was changed once, condi-
tioned medium of MSCs (supernatant) was collected at
48 hours and filtered through a 0.2-μm filter. Super-
natant was preserved at −20°C until its following injec-
tion. Supernatant was injected daily (250 μl/rat, ip) into
supernatant- treated group.
Labeling of the MSCs for assessing of in-vivo migration
MSCs were labeled by fluorescence cell membrane
tracker, CM-DiI™ (Invitrogen, Carlsbad, CA, USA). CM-
DiI was prepared under manufacturer’s protocol. The
medium of cultured cells was removed and 1 ml of CM
-DiI was added to cells in T 25 cm2 flask. The cells was
incubated in 37°C for 5 minutes and then in 4°C for
15 minutes. Then medium was added to cells and incu-
bated for overnight. After 24 h, about 1 × 106 MSCs
was transplanted via tail vein injection. Twenty four
hours after cell transplantation, animals were anesthe-
tized and pancreases were obtained. The pancreas was
then processed for paraffin embedding. Serial sections
of tissues were prepared. The slides were deparaffi-
nized and rehydration process was performed. Pancre-
atic tissues were then assessed under fluorescent
microscope. The sections counterstained with Hoechst
staining solution (Sigma-Aldrich, St. Louis, MO, USA).
Blood glucose monitoring and insulin levels
measurements
Blood glucose of all animals were measured weekly by
glucometer for 42 days. Animals were considered dia-
betic when blood glucose levels were higher than
300 mg/dl for two consecutive times.
For serum insulin measurements, blood samples were
collected from animals by weekly after intervention
(week 1, 2, 4 and 6). Serum insulin levels were measured
by rat insulin ELISA Kit (Mercodia AB Inc, Sweden)
under the protocol of manufacturer.
Immunohistochemical analysis
Animals were anesthetized and perfused intracardially with
4% paraformaldehyde/PBS. Pancreatic tissues were dis-
sected and soaked in 4% paraformaldehyde. Fixed tissues
were then processed for paraffin embedding with tissue
processing. Pancreatic sections stained with Hematoxylin/Eosin. Immunohistochemical detection of insulin was
performed on 4 μm sections using a standard chain
polymer-conjugated technique as described previously
on paraffin-embedded tissues of pancreas specimens
[25]. Briefly, after deparaffinization, tissue sections were
immersed in methanol containing 0.3% hydrogen perox-
ide to block endogenous peroxidase activity. Protein
blocker was then used for blocking non-specific bind-
ing. Antigen was retrieved by autoclaving in citrate buf-
fer (pH 6.0). The sections were incubated with primary
Anti- insulin antibody (guinea pig polyclonal to insulin,
ab7842, Abcam, Cambridge, UK) at 4°C overnight and
then incubated with rabbit polyclonal secondary anti-
body (Rabbit polyclonal secondary antibody to guinea
pig IgG - H&L (HRP), ab6771, Abcam, Cambridge, UK)
for 1 hour at room temperature. The slides were washed
and visualized using 3, 3-diaminobenzidine, (DAB; DAKO,
Glostrup, Denmark). The sections were counterstained
with heamtoxylin (Dako, Glostrup, Denmark). Finally
dehydration process was performed and slides were ob-
served under light microscope.
Statistical analyses
Statistical analysis was carried out by Prism (Version 5,
Graph Pad Software Inc). All the group values were
expressed as means ± SEM. Differences among groups
were determined by a one-way ANOVA. P < 0.05 was
considered as significant.
Results
Isolation and characterization of cultured MSCs
The isolated MSCs showed homogenous fibroblastic like
morphology in vitro that tightly attached to the culture dish
(Figure 1). Results of flow cytometric analysis on expression
of cell surface antigens shown that MSCs were expressed
CD44, CD73, CD105, CD106, and CD90 while were nega-
tive for CD11b, CD31, CD34, and CD45 (Figure 1).
Tracking of transplanted MSCs in pancreatic tissues
After transplantation of CM-DiI+-MSCs, serial sections
of the pancreatic tissues were assessed to detect migra-
tion of CM-DiI -positive cells in pancreatic section. The
sections stained with CM-DiI were fire red under fluor-
escent microscope (Figure 2).
Induction of diabetes type 1
Three days after STZ injection, most rats became hyper-
glycemic with mean blood glucose levels of 445.40 ±
29.91. Elevated blood glucose levels were continued up
to the end of experiment (547.20 ± 17.07) (Figure 3).
Also, Immunohistochemical analysis of pancreatic tis-
sues at the end of study showed that islets of pancreas
were almost destroyed after receiving a single dose of
STZ (Figure 2).
Figure 1 Morphology of mesenchymal stem cells and their characterization. A, Mesenchymsl stem cells in passage 3, cells with fibroblast- like
morphology. B, Characterization of rat BM-MSC surface markers using flow cytometry. Flow cytometric analyses showed that cultured cells were positive
for CD44, CD73, CD90, CD105 and CD106. These cells were negative for CD11b, CD31, CD34, and CD45. The respective isotype control is shown as black
line. The data are representative of three independent experiments.
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Figure 2 I, Assessment of CM-Dil+-MSCs homing into pancreatic tissues 24 hours after transplantation. (A) Image of MSCs implantation in
the pancreas (red points). (B) Counterstaining staining was performed using Hoechst (Blue). II, Immunohistochemistry staining of pancreatic
tissues of different animals with anti-insulin antibody at the end of study. Normal control (A), diabetic control, islets were destroyed after exposing
with STZ (B) MSCs-treated group (C), supernatant treated group (D), and MSCs + supernatant treated group (E) at the end of experiment. Size
and number of islets were increased after the treatment particularly in MSCs + supernatant treated group. Arrows, islets of Langerhans. Sections
(5 μm) are magnified × 200.
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administration and co-administration of MSCs with super-
natant on blood glucose of rats
The effect of transplantation of MSCs, supernatant and
co-administration of MSCs with supernatant on blood
glucose is shown in Figure 3. There was significant dif-
ference in blood glucose values among the weeks of ex-
periments (1–6 weeks) in all treated group. Second
transplantation of MSCs reduced blood glucose levels
at week 4, while MSCs + supernatant administration
significantly reduced blood glucose from week 2 after
treatment (Figure 3). Results showed that supernatant
of MSCs could not reduce blood glucose as good as
MSCs. Blood glucose was significantly reduced in MSCs +
supernatant treated group compared to MSCs and super-
natant groups at the end of experiment (Figure 3).
Effect of MSCs transplantation, supernatant
administration and co-administration of MSCs with super-
natant on insulin levels of rats
MSC-treated group exhibited significant higher insulin
levels after the second transplantation at week four,
(10.80 ± 1.32 vs. 3.00 ± 1.58, P < 0.01) when compared to
diabetic normal group. Also there was a significant in-
crease in insulin levels in MSCs + supernatant group when
compared to diabetic normal group (15.20 ± 1.530 vs.
3.00 ± 1.58, P < 0.001) at week four. The results showed
that MSCs + Supernatant increased serum insulin levels
more than MSCs at week four. Unlike, there was no sig-
nificant difference between insulin levels values in super-
natant treated group when compared to diabetic animals
at week four (5.40 ± 1.14 vs. 3.00 ± 1.58) (Figure 4).
At the end of study, day 42, significant difference in
insulin levels was observed in all treated groups; MSCs
treated (21.00 ± 4.16 vs. 2.40 ± 1.14, P < 0.001), super-
natant treated (8.12 ± 2.05 vs. 2.40 ± 1.14, P < 0.05) and
MSCs + supernatant treated animals (28.80 ± 1.83 vs.
2.40 ± 1.14, P < 0.001) compared to diabetic controls. Also,
our results indicated that MSCs + supernatant treated
group showed higher increase in insulin levels when com-
pared to MSC treated group (P < 0.05) (Figure 4).
Immunohistochemical analysis of pancreatic tissues
Immunohistochemical assessment of pancreas indicated
that both MSCs and supernatant initiates pancreatic re-
generation after transplantation into recipient diabeticrats. Partial pancreatic renewal was evidenced by emerge
of small islets in pancreatic tissues. The number and size
of islets per section in MSCs treated animals were higher
than supernatant groups. Also the number and sizes of
islets per section in MSCs + supernatant group were
higher than other treated groups (Figure 2).
Effect of MSCs, supernatant administration and co-
administration of MSCs with supernatant on body weight
of rats
Six weeks after induction of DM, diabetic controls ex-
hibited significant reduction in their body weight com-
pared to before induction of diabetes (182.20 ± 8.60 vs.
231.60 ± 8.35, P < 0.001). There was significant difference
between body weight of MSCs -treated diabetic rats and
diabetic control animals (223.20 g ± 3.50 vs. 182.20 g ±
8.60, P < 0.001). There was a significant increase in body
weight of supernatant- treated rats when compared to
diabetic control rats at week six (255.80 g ± 7.73 vs.
182.20 g ± 8.60, P < 0.01) (Figure 2). Our results also
showed that body weight improvement in MSCs + super-
natant received animals was significantly higher than
MSCs and supernatant groups respectively (267.20 g ±
4.16 vs. 223.20 g ± 3.50, P < 0.01) (267.20 g ± 4.16 vs.
255.80 g ± 7.73, P < 0.05).
Discussion
Mesenchymal stromal cells are multipotent stem cells
showing tremendous potential for regenerative medicine
due to their ability in: self-renewing, differentiation into
a variety of tissues and their availability in almost all
postnatal organs and tissues [26-28]. It has been pro-
posed that the ability of MSCs to secrete a variety of fac-
tors that change tissue microenvironment functionally is
more important than their trans-differentiation ability in
affecting tissue regeneration [29,30]. Therefore, besides
their ability to differentiate into many cell lines, the se-
cretion of a wide range of biological molecules by MSCs,
such as growth factors, cytokines and chemokines, es-
tablishes their biologically effective role under condition
of injury [29-33]. Although the exact mechanism of ac-
tion of MSCs in tissue regeneration is poorly under-
stood, MSCs therapy has attracted a great deal of
attention for the treatment of diabetes mellitus. In this
study we planned a comparative study on the influence
of MSCs transplantation, supernatant administration and
Figure 3 (See legend on next page.)
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Figure 3 Blood glucose levels in normal, diabetic and treated rats during the experiment. All values are mean ± SEM. A, Blood glucose
levels in diabetic controls during the weeks of experiment, elevated blood glucose levels were continued up to the end of experiment. *,
blood glucose values at weeks 1–6 vs. 3 days after STZ. B, C, D, blood glucose levels in supernatant, MSCs and MSCs + supernatant -treated
groups respectively during the weeks of experiment. *; blood glucose values at weeks 1–6 vs. 3 days after STZ. E, blood glucose values in different
groups at the end of study. *, MSC, supernatant, MSC-supernatant groups vs. diabetic control. #, diabetic, supernatant, MSC-supernatant groups vs.
MSC group. *,P < 0.05; **, P < 0.01; ***, P < 0.001. #, P < 0.05; ##, P < 0.01; ###, P < 0.001.
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hyperglycemia in STZ-induced diabetic rats.
In present study, migration of MSCs to injured tissues
was demonstrated by observation of CM-DiI+-MSCs in
pancreatic sections under fluorescent microscope. Small
islets regeneration observed in immune-histochemical
analysis accompanying with elevation of insulin levels
and decrease in blood glucose levels in diabetic-MSCs-
treated animals, indicating survival of transplanted
MSCs in animal’s tissues.
Our results showed that, although single transplantation
of MSCs could prevent further rise of blood glucose inFigure 4 Effect of MSCs transplantation, supernatant administration a
levels and body weights in different animals. Values are mean ± SEM. A,
week 6. C, body weight of animals at the end of study. *; MSC, supernatant, MS
MSC-supernatant groups vs. MSC group.*, P < 0.05; **, P < 0.01; ***,P < 0.001. #, Pdiabetic rats, but it could not significantly control hypergly-
cemia as good as when repeated injection of MSCs were
used. We found that single transplantation of 2.5 × 106
MSCs could not reduce blood glucose levels of diabetic ani-
mals, but repeated injection of same dose of MSCs at the
week of four, could significantly reduce blood glucose levels
compared to diabetic controls. It is supposed that the first
injection of MSCs provide a suitable environment by releas-
ing some growth factor and cytokines, in which survival,
docking and homing of incoming MSCs is being facilitated.
In contrary with our study, some evidences reported
that single transplantation of MSCs could reduce bloodnd co-administration of MSCs with supernatant on serum insulin
serum insulin levels at week 4. B, serum insulin levels at the end of study at
C-supernatant groups vs. diabetic control group. #; Diabetic, supernatant,
< 0.05; ##,P < 0.01; ###, P < 0.001.
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study designed by Dong and et.al, performing an allo-
geneic diabetic mesenchymal stem cells transplantation
in STZ-induced diabetic rats, they reported that single
injection of 2- 4 × 106 MSCs reduced blood glucose
levels in recipient rats compared to diabetic controls
(27.8 ± 2.1 mM/l vs. 17.7 ± 3.9 mM/l , P < 0.05). They
have indicated that small quantity of transplanted MSCs
survived and transdifferentiated into insulin-producing
cells in pancreas of recipient rats [14].
Efficacy and safety of repeated transplantation of MSCs
have been assessed by some other studies in different or-
gans. They exhibited that repeated administration of
MSCs is more effective than single administration in im-
proving damaged tissues [35-37]. Repeated versus single
transplantation of MSCs for improving of liver injury in
mice was studied by Miryounesi et al., they found that
transplanting 3 × 106 MSCs in three divided doses im-
proved survival, liver fibrosis and necrosis compared to in-
jection of the same number of MSCs in a single dose.
They have also exhibited that repeated injection of MSCs
was three times more effective in homing of transplanted
cells compared to the single transplant [35].
Using supernatant of MSCs, so-called conditioned
medium (CM), in tissue regeneration comes from the idea
that MSCs could have beneficial effect even if they do not
engraft in target tissues. Bi et al. demonstrated that ad-
ministration of conditioned medium from bone marrow-
derived MSCs in a model of acute kidney injury (AKI)
increased survival and limited renal injury in mice. They
have also showed that conditioned medium of MSCs, in-
duced migration and proliferation of kidney-derived epi-
thelial cells and significantly diminished cisplatin-induced
proximal tubule cell death in vitro [38].
In the study by Timmers et al., conditioned medium
of MSCs was used to improve myocardial infarction
(MI) in pigs. They have found intravenous human
MSCs-conditioned medium increased capillary density
and preserved cardiac function through enhancing
myocardial perfusion in pigs with MI [39].
Our finding indicated that although there was a differ-
ence between blood glucose and insulin levels of super-
natant treated group compared to diabetic controls at the
end of study but, it could not reduce blood glucose as effi-
cient as MSCs .Interestingly our results showed that super-
natant of MSCs could be more beneficial if it would be
administered accompany with MSCs. Co-administration of
MSCs with supernatant of MSCs in diabetic rats could sig-
nificantly increase insulin (28.80 ± 4.09) and reduce blood
glucose (285.8 ± 10.11) levels in experimental animals com-
pared to other treated groups. We also found that co-
administration of MSCs with supernatant reduced blood
glucose from week 2 after treatment while, transplantation
of MSCs reduced blood glucose levels at week 4. Wesuppose that supernatant could help MSCs to migrate to-
ward damaged pancreatic tissues via providing a micro-
environment for better homing.
Immunohistochemical analysis of pancreas showed an
increase in size and number of islets in each slice in
MSCs + Supernatant group compared to other treated
group. Our results showed that co- administration of MSCs
with supernatant could be an effective tool in regeneration
of the injured pancreatic tissues. It seems that conditioned
medium of MSCs which containing a variety of growth fac-
tors, cytokines and immunomodulatory factors, could help
MSCs in better survival, proliferation and eventually hom-
ing toward damaged pancreatic tissues and higher differen-
tiation into pancreatic cells then after.
We also found that diabetic control animals lost their
body weight and became slim during the experiment. In
contrast, administration of MSCs and their supernatant to
diabetic animals not only could prevent loosing but also
could increase their body weight significantly compared to
normal diabetic rats. Co-administration of MSCs with
supernatant have synergistic effect on the body weight of
animals improving their body weight significantly more
than either MSCs or supernatant treated animals.
Conclusion
In summary, our study was designed to compare differ-
entiation and paracrine properties of MSCs in control of
diabetes mellitus induced by STZ. Our results indicated
that co-administration of MSCs and supernatant could
control the hyperglycemia in diabetic rats more than ei-
ther group alone. Therefore, it could be assumed that
there is synergistic effect between MSCs and supernatant
of MSCs in pancreatic regeneration of diabetic animals.
This approach may be considered to be applied in cell
therapy of diabetic patients.
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